A long-term extension study is a clinical extension trial that follows a preceding trial and continues the treatment or follow-up over a longer period. It primarily serves to gain data on the longer-term safety, tolerability and use of an intervention. Whether and under what conditions participants from the initial trial are enrolled is determined by an independent protocol.<\/p>\n
Development programs require information on a sufficiently long exposure and follow-up in the case of an intended long-term use. ICH E8(R1) states that for intended long-term use, trials with extended drug exposure should be conducted and the duration of the effect co-determines the duration of follow-up. An extension trial can supplement such data by continuing to follow individuals from an earlier trial.<\/p>\n
The trial is not automatically a continuation without new requirements. Objective, population, endpoints, duration, safety monitoring, data processing and informed consent are to be defined for the extension. Participants must meet the criteria of the extension trial and give effective informed consent anew or on a continuing basis, insofar as this is required by the applicable procedure. The transition must be documented cleanly so that exposure and observation time remain traceable.<\/p>\n
Many long-term extension studies are conducted open-label and allow further treatment with the investigational intervention after completion of the initial trial. However, being open-label is not a defining characteristic of every extension trial. An open-label extension design can facilitate the acquisition of long-term safety data, but limits the randomized comparison from the original trial. Statements on comparative long-term efficacy therefore require a particularly cautious interpretation.<\/p>\n
The protocol should determine exposure duration, dose adjustments, concomitant medication, discontinuation criteria, visit schedule, laboratory and safety examinations as well as the collection of clinical target variables. For open-label trials, ICH E8(R1) recommends predefined decision rules for recruitment, treatment, participant management, safety reports and the collection of the target variables. As far as possible, blinded roles or independent assessments can reduce remaining risks of bias.<\/p>\n
Interpretation of long-term data<\/strong><\/p>\n The enrolled population of an extension is frequently selected: Participants must have completed the initial trial, be willing to continue and, if applicable, remain under the previous treatment. Individuals with early discontinuation, intolerance or lack of efficacy can thus be underrepresented. Even if all suitable individuals are included, the extension is not an unchanged reflection of the original randomized population.<\/p>\n Long-term data are nevertheless valuable for the safety profile if exposure, adverse events, discontinuations and missing data are presented transparently. The analysis must consider the limited comparability and possible time-dependent influences. An observed long-term course cannot readily be read as a causal advantage over the previous control treatment if this treatment is no longer continued in parallel after the transition.<\/p>\n For the evaluation, the time axis is therefore to be clearly indicated: The start of the initial trial, transition into the extension, actual treatment exposure and duration of follow-up must not be combined without justification. Only in this way can it be recognized on which data basis long-term safety observations rest.<\/p>\n The initial trial is the preceding trial with its own research question, randomization and primary analysis. The long-term extension study is a subsequent, independently planned trial, even if it builds on its population and data. The data of both trials must be linkable via suitable identifiers without mixing the respective analysis populations and time periods.<\/p>\n An open-label trial describes that allocation or treatment are known. It can be an extension trial, but does not have to be. Conversely, an extension trial can contain partially blinded elements. “Open label” therefore indicates a blinding characteristic of the design, while “long-term extension study” describes the follow-on and the extended observation.<\/p>\n Operationally, transition criteria, new informed consents, supply with trial medication and safety follow-up must be organized without a gap. Different countries, trial sites or recruitment periods can influence the duration of exposure. The clinical study report should therefore traceably indicate the duration and extent of exposure, discontinuations, reasons for discontinuations and the origin of the analyzed data.<\/p>\n Full-service CROs such as Mediconomics support the planning of the follow-on design, informed consent and visit processes as well as long-term safety and data management. Project management, monitoring, pharmacovigilance, biostatistics and medical writing coordinate transitions between trials, the collection of exposure and adverse events, data cleaning and the transparent reporting of the long-term data.<\/p>\n Is a long-term extension study always conducted open-label?<\/strong><\/p>\n No. Many extensions are open-label, but the term primarily describes the subsequent extended observation and not necessarily the blinding status.<\/p>\n Does the extension replace the randomized initial trial?<\/strong><\/p>\n No. It supplements in particular long-term data. The original randomized comparative statement remains tied to the design of the initial trial.<\/p>\n Why are discontinuations in the extension important?<\/strong><\/p>\n They influence who is observed over a long time and are therefore central for the interpretation of safety and tolerability.<\/p>\n A long-term extension study is a clinical extension trial that follows a preceding trial and continues the treatment or follow-up over a longer period. It primarily serves to gain data on the longer-term safety, tolerability and use of an intervention. Whether and under what conditions participants from the initial trial are enrolled is determined by […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6688","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6688\/revisions"}],"predecessor-version":[{"id":7470,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6688\/revisions\/7470"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6688"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Differentiation from the initial trial and open-label trial<\/h2>\n
Relevance for clinical trials<\/h2>\n
Frequently Asked Questions (FAQ)<\/h2>\n
Regulatory references<\/h2>\n
\n